thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-28. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
=== Sandwich debate === There is an ongoing debate about whether a hot dog, fully assembled in its bun with condiments, fits the description of a sandwich. Merriam-Webster has stated that a hot dog is indeed a sandwich. In 2015, the National Hot Dog and Sausage Council (NHDSC), on the other hand, declared that a hot dog is not a sandwich. Hot dog eating champions Joey Chestnut and Takeru Kobayashi agree with the NHDSC, as does Nathan's Famous, the host of a significant hot dog eating contest. United States Supreme Court justice Ruth Bader Ginsburg also weighed in on the matter, stating that a hot dog might be categorized as a sandwich, but ultimately it comes down to the definition of a sandwich. She went on to acknowledge that a hot dog bun is a single roll that is not sliced all the way through, and in that way is similar to a submarine sandwich.
Gly + [Glu(-Cys)]n+1-Gly Thus, the two substrates of this enzyme are glutathione and [Glu(-Cys)]n-Gly, whereas its two products are Gly and [Glu(-Cys)]n+1-Gly. This enzyme belongs to the family of transferases, specifically the aminoacyltransferases. The systematic name of this enzyme class is glutathione:poly(4-glutamyl-cysteinyl)glycine 4-glutamylcysteinyltransferase. Other names in common use include phytochelatin synthase, and gamma-glutamylcysteine dipeptidyl transpeptidase.
==== MeSH E05.337.250 – clinical trials ==== MeSH E05.337.250.200 – clinical trials, phase i MeSH E05.337.250.210 – clinical trials, phase ii MeSH E05.337.250.220 – clinical trials, phase iii MeSH E05.337.250.230 – clinical trials, phase iv MeSH E05.337.250.365 – controlled clinical trials MeSH E05.337.250.365.500 – randomized controlled trials MeSH E05.337.250.500 – multicenter studies
== Tissue and subcellular distribution == Galectin-7 is found both intracellularly and extracellularly. It is secreted via a non-classical, endoplasmic reticulum–Golgi–independent pathway and can form galectin–glycan lattices by clustering on cell-surface receptors. It is also present in primary cilia of epithelial cell types such as those of the airway and kidney.
Sources: en.wikipedia.org
RAC/The Sunday Times Taste of Britain Best Restaurant Award 1984 Decanter Magazine Restaurant of the Year 1989 The Good Hotel Guide Cesar Award 1995 Egon Ronay's Guide Restaurant of the Year 1996 Hotel & Restaurant Magazine Seafood Restaurant of the Year 1998, 1999, 2000, 2001 and 2003 The AA Award – English Seafood Restaurant of the Year Award 2002 For the man:
HMRC reverses the plan for its self-assessment helpline, announced the previous day, following criticism from the public and MPs. The Senedd approves Vaughan Gething as the next First Minister of Wales. The London Clinic, where the Princess of Wales underwent abdominal surgery, announces that "any breach" of patient confidentiality will be investigated after reports a member of staff tried to access her private records. 21 March The Bank of England leaves interest rates unchanged at 5.25%, for the fifth time in a row. A report published by the Parliamentary and Health Service Ombudsman recommends women born in the 1950s who were affected by the 2010 changes to the state pension age should receive compensation of between £1,000 and £2,900. 22 March Following media speculation about her health, it is revealed that the Princess of Wales has been diagnosed with cancer and is undergoing treatment. Wetherspoons reports an eightfold increase in pre-tax profits during the first six months of the 2023–24 financial year. 23 March – A report compiled by the Resolution Foundation indicates a rise in the number of people leaving work due to long-term health conditions, with the number of people inactive due to long-term health conditions rising from 2.1 million in 2019 to 2.8 million in October 2023, the longest sustained rise since 1994–1998 when records began. The UK is also the only country in the G7 not to return to pre-pandemic employment levels.
Pratītya: "having depended". The term appears in the Vedas and Upanishads in the sense of "confirmation, dependence, acknowledge origin". The Sanskrit root of the word is prati* whose forms appear more extensively in the Vedic literature, and it means "to go towards, go back, come back, to approach" with the connotation of "observe, learn, convince oneself of the truth of anything, be certain of, believe, give credence, recognize". In other contexts, a related term pratiti* means "going towards, approaching, insight into anything". Samutpāda: "arising", "rise, production, origin" In Vedic literature, it means "spring up together, arise, come to pass, occur, effect, form, produce, originate". Pratītyasamutpāda has been translated into English as dependent origination, dependent arising, interdependent co-arising, conditioned arising, and conditioned genesis. Jeffrey Hopkins notes that terms synonymous to pratītyasamutpāda are apekṣasamutpāda and prāpyasamutpāda. The term may also refer to the twelve nidānas, Pali: dvādasanidānāni, Sanskrit: dvādaśanidānāni, from dvādaśa ("twelve") + nidānāni (plural of "nidāna", "cause, motivation, link"). Generally speaking, in the Mahayana tradition, pratityasamutpada (Sanskrit) is used to refer to the general principle of interdependent causation, whereas in the Theravada tradition, paticcasamuppāda (Pali) is used to refer to the twelve nidānas.
=== United States === In the United States, the addition of pure thujone to foods is not permitted. Foods or beverages that contain Artemisia species, white cedar, oakmoss, tansy, or yarrow, must be thujone-free, which in practice means that they contain less than 10 parts per million thujone. Other herbs that contain thujone have no restrictions. For example, sage and sage oil (which can be up to 50% thujone) are on the Food and Drug Administration's list of generally recognized as safe (GRAS) substances. Absinthe offered for sale in the United States must be thujone-free by the same standard that applies to other beverages containing Artemisia, so absinthe with small amounts of thujone may be legally imported.
The fission of one atom of uranium-235 releases 202.5 MeV (3.24×10−11 J) inside the reactor. That corresponds to 19.54 TJ/mol, or 83.14 TJ/kg. Another 8.8 MeV escapes the reactor as anti-neutrinos. When 23592U nuclei are bombarded with neutrons, one of the many fission reactions that it can undergo is the following (shown in the adjacent image):
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.